"As Advaxis is primarily focused on developing neoantigen-directed therapeutics, this license agreement will allow for the clinical potential of ADXS-HER2 to be explored in osteosarcoma without financial support from Advaxis, building on earlier work performed by us with ADXS-HER2 in a Phase 1

  Selects Bladder Cancer as Third ADXS-HOT Drug Candidate to Take into the Clinic after Non-Small Cell Lung and Prostate Cancers Advances Goal to Have Five Neoantigen-Based Drug Candidates in Clinical Evaluation by 4Q 2019 "This is an exciting time for Advaxis as we prepare to initiate the first

PRINCETON, N.J.--( BUSINESS WIRE )-- Advaxis, Inc.  (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the Company’s

"With our announcement today of plans for a second IND submission for an ADXS-HOT construct in prostate cancer, we feel confident we can reach proof-of-concept for these off-the-shelf therapeutics in a relatively rapid and cost-effective manner." PRINCETON, N.J.--( BUSINESS WIRE )-- Advaxis, Inc.

-ADXS-NEO is being evaluated in a Phase 1 clinical trial in various cancers -First patient dosed is being treated for NSCLC "We are extremely pleased to advance ADXS-NEO into the clinic. This program brings our clinically-validated Lm Technology to the cutting-edge area of neoantigen

Annual cash burn will be reduced to approximately $50 million from approximately $80 million through a combination of portfolio rationalization and headcount reduction Conference call begins today at 11:00 a.m. Eastern time   "Everything we are striving to accomplish depends on focus and optimal

"Molly has significant experience as a public company CFO in the healthcare industry, including immuno-oncology, and in managing the capital efficiency and financial requirements of a development-stage biotechnology company like Advaxis. We are very pleased to add Molly to our executive management

Durable complete response seen in a recurrent / metastatic cervical cancer patient previously treated with chemoradiation and systemic-dose chemotherapy plus bevacizumab "ADXS11-001 immunotherapy in squamous or non-squamous persistent/recurrent metastatic cervical cancer: Results from stage 1 [and

"Improvements in the care and treatment of highly refractory prostate cancer, a traditionally difficult type of cancer to treat, are vital. These early results show a safe and tolerable profile for ADXS-PSA alone or in combination with KEYTRUDA" PRINCETON, N.J.--( BUSINESS WIRE )--   Advaxis, Inc.

PRINCETON, N.J.--( BUSINESS WIRE )--   Advaxis, Inc.    (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announced today the upcoming release of financial results for the six months ended April 30, 2018, to take